View Post

Brooklyn ImmunoTherapeutics Announces Initiation of Phase 2 Trial of IRX-2 in Combination with Pembrolizumab and Chemotherapy in Triple Negative Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Brooklyn ImmunoTherapeutics From: businesswire.com Brooklyn ImmunoTherapeutics LLC (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, today announced the initiation of an open-label Phase 2 clinical trial of IRX-2 in combination with pembrolizumab (Keytruda®) and chemotherapy in triple negative breast cancer (TNBC). The trial will be conducted at the …

View Post

Drug is promising against pancreatic and breast cancers

In Clinical Trials by Barbara Jacoby

Source: Georgia State University From: eurekalert.org ProAgio, created from a human protein, targets the cell surface receptor integrin αVβ?, which is expressed on cancer-associated fibroblasts ProAgio, a drug developed by Georgia State University biology professor Zhi-Ren Liu and his team, is effective at treating pancreatic cancer and prolonging survival in mice, according to a study published in the journal Cellular …

View Post

Removing microRNAs from triple-negative breast cancer cells can reverse its spread

In In The News by Barbara Jacoby

By: University of Westminster From: medicalxpress.com A new study led by the University of Westminster shows that removing small genetic parts of our genomes called microRNAs from triple negative breast cancer cells can reverse its spread. The study, published in the International Journal of Molecular Sciences, also identified that microRNAs could be targeted for early detection and treatment of triple …

View Post

Ayala Pharmaceuticals Announces First Patient Dosed in Phase 2 TENACITY Clinical Trial of AL101 for the Treatment of Patients with Notch-Activated Triple Negative Breast Cancer

In Clinical Trials by Barbara Jacoby

Source: Ayala Pharmaceuticals From: globenewswire.com Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced the first patient dosed in the Phase 2 TENACITY clinical trial of its potent, selective small molecule AL101, for the treatment of patients with Notch-activated recurrent or metastatic …

View Post

Irish researchers discover potential new therapy for chemotherapy-resistant breast cancer

In In The News by Barbara Jacoby

By: Caitlín Griffin From: irishexaminer.com A potential new therapy for chemotherapy-resistant breast cancers has been discovered by Irish scientists. The study, led by researchers at the Royal College of Surgeons Ireland (RCSI) University of Medicine and Health Sciences, shows that they have discovered a molecule that can kill cells of a hard-to-treat subtype of breast cancer, which could lead to …

View Post

Triggering antiviral immune response in certain breast cancers

In Clinical Trials by Barbara Jacoby

By: Molly Chiu From: bcm.edu Researchers at Baylor College of Medicine have discovered how therapeutics targeting RNA splicing can activate antiviral immune pathways in triple negative breast cancers (TNBC) to trigger tumor cell death and signal the body’s immune response. A new study published in Cell shows that endogenous mis-spliced RNA in tumor cells mimics an RNA virus, leading tumor …

View Post

Triple-Negative Breast Cancer: Assessing the Role of Immunohistochemical Biomarkers on Neoadjuvant Treatment

In Clinical Trials by Barbara Jacoby

From: dovepress.com Objective: This study aimed to investigate the influence of immunohistochemical (IHC) biomarkers in the response to neoadjuvant chemotherapy (NACT) and survival outcomes in the subset of locally advanced triple-negative breast cancer (TNBC). Materials and Methods: The epidermal growth factor receptor (EGFR), androgen receptor (AR), cytokeratins (CK5/6, CK14 and CK17), Ki67 and p53 immunohistochemistry were evaluated on 171 cases …

View Post

Keytruda and Chemotherapy Combination Broadens Number of Treatable Patients with TNBC

In In The News by Barbara Jacoby

By: Conor Killmurray From: curetoday.com In an interview with CURE®, lead study investigator of the Keynote 355 trial, Dr. Hope S Rugo, discusses the results of the study that led to the FDA approval of the combination therapy and what further data means for certain patients with metastatic triple-negative breast cancer. In November, the Food and Drug Administration (FDA) granted …

View Post

Gilead Advances Oncology Portfolio With New Data From Phase 3 ASCENT Trial of Trodelvy® in Metastatic Triple Negative Breast Cancer

In Clinical Trials by Barbara Jacoby

From: .businesswire.com Gilead Sciences, Inc. (Nasdaq: GILD) is presenting new data from the Phase 3 ASCENT trial of Trodelvy® (sacituzumab govitecan-hziy) in metastatic triple-negative breast cancer (mTNBC) at the 2020 San Antonio Breast Cancer Symposium being held virtually December 8-11, 2020. The new data and analyses from the ASCENT trial continue to demonstrate the high clinical activity of Trodelvy in …

View Post

New Pharma Trials Making Big Gains in Fight Against Triple-Negative Breast Cancer (TNBC)

In Clinical Trials by Barbara Jacoby

Source: USA News Group From: prnewswire.com Triple-negative Breast Cancer (TNBC) is a highly aggressive subtype that accounts for 15-20% of breast cancer cases and 25% of all breast cancer deaths. Unlike other breast cancers, treatments for TNBC involving hormone therapy and drugs that target HER2 protein are not helpful. With a dire need for new forms of treatment, there’s plenty of optimism …